Novartis, Astellas Intend To Disprove Eczema Treatments’ Cancer Risk

Novartis and Astellas aim to use ongoing studies to convince FDA to remove a requirement for a "black box" warning of potential cancer risk in labeling for their topical calcineurin inhibitors